# Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency

> **NCT06205758** · — · UNKNOWN · sponsor: **Yi Han** · enrollment: 1600 (estimated)

## Conditions studied

- Heart Failure
- Levosimendan
- Milrinone
- Efficacy
- Safety

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06205758
- **Lead sponsor:** Yi Han
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-16
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 1600 (ESTIMATED)
- **Last updated:** 2024-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06205758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06205758, "Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06205758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*